MR DNA

MR DNA is a biotech startup established in 2011, specializing in Next Gen Sequencing and Bioinformatics Services. The company offers collaborative service pricing for Illumina, 454, and ion torrent sequencing, as well as a full range of bioinformatics and collaborative analysis. With a focus on microbiome research, MR DNA provides 16S RNA pyrosequencing service, microbiome, metagenome, transcriptomes, genomes, bioinformatics, small RNA, illumina, ion Torrent, 454 pyrosequencing service at competitive rates. Additionally, the company is involved in developing next-generation diagnostic assays in collaboration with partners. MR DNA's expertise lies in inexpensive methods to evaluate microbial diversity using the bacterial tag-encoded FLX amplicon pyrosequencing bTEFAP(R) approach, and a range of other services including genome sequencing, metagenomes, microbiomes, transcriptomes, SNP, AFLP pyrosequencing, and more. Overall, MR DNA presents an intriguing investment opportunity in the Biopharma, Biotechnology, and Pharmaceutical industries with its cutting-edge offerings and experienced team. While the last investment details are not available, MR DNA's innovative approach to molecular research and diagnostics positions it as a promising prospect for potential investors in the biotech space.